New treatment option for central and peripheral muscle spasm to reduce pain, muscle tension and improve mobility1
A new treatment for back pain associated with muscle spasm has been licensed for use in the UK (28th May 2020). Myopridin® (pridinol mesilate) 3mg tablets is indicated for the treatment of central and peripheral muscle spasm including lumbar pain, torticollis, general muscle pain in adults2.
Suitable for acute pain and spasm, Myopridin® is a rapid-acting treatment which starts to take effect within 0.5 to 2 hours to reduce the pain1,2. It targets the muscarinic receptors of the α-motor neurons in the spine, lessening muscle spasms and thereby alleviating pain. A substantial proportion of patients with back pain have muscle spasm, with evidence showing that pain may cause muscle spasms and that muscular activity can be painful1.
In all adults, low back and neck pain remain the biggest cause of ill health overall in England3. Back pain results in the loss of 4.1 million working days a year4, incurs direct costs of over £1.6 billion8 and accounts for 7% of all GP consultations7. Furthermore, neck pain is the fourth highest cause of disability in the UK3, leading to considerable pain, disability and economic cost5.
Recent studies have highlighted the growing issue of acute back pain during the pandemic, with a survey of people working remotely during the UK lockdown finding that 81% of respondents were experiencing some back, neck or shoulder pain9. In addition, The Institute of Employment Studies reports that 55 per cent of respondents have experienced new aches and pains in their back, as well as in the shoulder (58%) and neck (56%) since switching to work from home10.
Current pharmacological management strategies to treat lower back pain and muscle spasm include benzodiazepines (e.g.Diazepam), opiates (e.g. Codeine, Tramadol) and Gabapentin; medicines which are associated with abuse and dependence 11-13. This poses a huge challenge for clinicians to manage patients suffering from lower back pain and neck pain effectively and as safely as possible.
For health care professionals across the multi-disciplinary team with an interest in pain management, Myopridin® is an efficacious antimuscarinic therapy, with a well-documented safety profile and no potential for addiction to pridinol is known 14,15. At the recommended dose, adverse effects are rare to uncommon and generally reversible. Further details on the safety profile of Myopridin can be found below. Myopridin is available as 3mg tablets with a recommended dose is half to one tablet of Myopridin 3mg tablets (pridinol mesilate) taken three times a day at a cost of less than 80p per day.
Myopridin is supported by an extensive evidence base, with studies suggesting that:
Mark Inker, General Manager at mibe Pharma Ltd comments, “We’re delighted to be able to offer Myopridin as an alternative treatment option for healthcare professionals seeking to reduce the burden of back pain. At mibe Pharma Ltd, we strive to ensure patients have access to efficacious and life-changing therapies. Myopridin very much fits into this vision, providing a valuable first line treatment as an alternative to existing therapies in the UK helping to reduce the pain associated with this debilitating condition. Pridinol has a strong heritage in other countries – with over 3 million people receiving the treatment in the 20 years it has been available in Germany17.”
Dr Abir Doger, Consultant in Anaesthetics and Pain Management, MBBS, FRCA, FFPMRCA, Midland Pain Clinic, comments, “This treatment option, newly launched in the UK, has the potential to increase the available pharmaceutical armamentarium for UK clinicians in dealing with difficult-to-treat pain associated with spasm. Myopridin is a fast acting, non-addictive, non-sedating muscle relaxant that has been in use within Europe for a number of years. It has the potential to offer an efficacious and tolerable solution.”